Investigation Report on China Cefuroxime Market, 2010-2019

As the second generation of cephalosporin, cefuroxime features broad antibacterial spectrum, high stability and few ...
Reference: 1509309
Price: $2,000.00
Tax included

General

Publisher:
CRI
Geography Covered
China
Publication Date
9/7/2015
Pages
40
Version:
2010
Charts:
40
Language
  • English
  • Chinese
Format
License

Description

As the second generation of cephalosporin, cefuroxime features broad antibacterial spectrum, high stability and few adverse effects which ensure its great activity against bacteria.
First developed by Glaxo Wellcom, cefuroxime entered Britain, Ireland, Germany and Italy in 1978 and the US in 1987. Due to its exact efficacy, cefuroximine has been widely used to treat infections caused by sensitive bacteria in many countries. Since the beginning of the 1990s, it has become the most popular anti-infectious agents and remained hardly susceptible to beta-lactamase even after it turned generic. And it has such dosage forms as dry suspension, tablet, capsule, dispersible tablet and injection.
Cephalosporin has developed fast since the beginning of the 21st century. Due to its widest application and best efficacy, cephalosporin has occupied an important position among anti-infectious agents. As people become increasingly aware of antibiotics, the use of injection will be gradually reduced to avoid cross infection and adverse effects. With the promotion and application of many oral drugs, dispersible tablet, effervescent tablet, sirup and solution will enjoy good market prospects.
Anti-infectious agent has been leading the medicine market especially when emergency arises. And cephalosporin, as a major variety of anti-infectious agent, occupies almost half of the market. As the most used cephalosporin, cefuroxime has reported sales increase since the appearance of its power injection. As cefuroxime is found to cross blood-brain barrier easily and exert little influence on coagulation function, it has become the first choice of carniocerebral department.
According to CRI's market survey, the sales value of cefuroxime in sample hospitals rose from over CNY 400 million in 2010 to over 600 million in 2014 and CAGR during this period exceeded 10%. ESSETI (Italy), GlaxoSmithKline (Italy), Medochemie Ltd. (Cyprus), SCCPC and GlaxoSmithKline plc. occupy the market, among which ESSETI (Italy) had the largest market share of about 28% for sales value in 2014.
Due to its wide application, cefuroxime will enjoy a vast market in future.

Readers can get at least the following information through this report:
-market size of cefuroxime in China
-competitive landscape of cefuroxime market in China
-price of cefuroxime made by different enterprises in China
-market outlook of cefuroxime in China

The author suggests the following groups of people purchase this report:
- Pharmaceutical Manufacturers
-investors/research institutions interested in Chinese medicine market
--any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1 Related Concepts of Cefuroxime
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Cefuroxime in China
2.1 Patent and Approval Information of Cefuroxime in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Cefuroxime Sales in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions

4 Survey on Market Share of Major Cefuroxime Manufacturers in China, 2010-2014
4.1 Market Share by Sales Value
4.2 Market Share by Sales Volume

5 Survey on Dosage Forms of Cefuroxime in China, 2010-2014
5.1 Share of Different Dosage Forms by Sales Value
5.2 Share of Different Dosage Forms by Sales Volume

6 Reference Price of Cefuroxime in Chinese Hospitals in 2014
6.1 SCCPC
6.2 GlaxoSmithKline (Italy)
6.3 ESSETI (Italy)
6.4 GlaxoSmithKline plc.
6.5 Medochemie Ltd.(Cyprus)

7 Major Manufacturers of Cefuroxime in Chinese Market, 2010-2014
7.1 SCCPC
7.2 GlaxoSmithKline (Italy)
7.3 China National Accord Medicines Corporation Ltd.
7.4 GlaxoSmithKline plc.
7.5 Medochemie Ltd. (Cyprus)

8 Market Outlook of Cefuroxime in China, 2015-2019
8.1 Forecast of Market Size
8.2 Forecast of Competitive Landscape

Table of Selected Charts

Chart Approval Information of Cefuroxime in China
Chart Cefuroxime Sales in China
Chart Sales Value of Cefuroxime in China, 2010-2014
Chart Sales Value of Cefuroxime in Some Regions in China, 2010-2014
Chart Sales Volume of Cefuroxime in China, 2010-2014
Chart Sales Volume of Cefuroxime in Some Region in China, 2010-2014
Chart Market Share of TOP5 Cefuroxime Manufacturers for Sales Value in China, 2010-2014
Chart Sales Value and Market Share of Cefuroxime Made by ESSETI (Italy) in China, 2010-2014
Chart Sales Value and Market Share of Cefuroxime Made by GlaxoSmithKline (Italy) in China, 2010-2014
Chart Sales Value and Market Share of Cefuroxime Made by Medochemie (Cyprus) in China, 2010-2014
Chart Sales Value and Market Share of Cefuroxime Made by SCCPC in China, 2010-2014
Chart Sales Value and Market Share of Cefuroxime Injection in China, 2010-2014
Chart Sales Value and Market Share of Cefuroxime Tablet in China, 2010-2014
Chart Sales Value and Market Share of Cefuroxime Capsule in China, 2010-2014
Chart Sales Value and Market Share of Cefuroxime Granule in China, 2010-2014
Chart Price of Cefuroxime Made by SCCPC in Some Chinese Cities in 2014
Chart Price of Cefuroxime Made by GlaxoSmithKline (Italy) in Some Chinese Cities in 2014
Chart Price of Cefuroxime Made by ESSETI (Italy) in Some Chinese Cities in 2014
Chart Price of Cefuroxime Made by GlaxoSmithKline plc. in Some Chinese Cities in 2014
Chart Price of Cefuroxime Made by Medochemie (Cyprus) in Some Chinese Cities in 2014

Scroll